New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
08:33 EDTDXCM, ABTDexCom reports settlement and license agreement with Abbott Diabetes Care
On July 2, DexCom (DXCM) entered into a Settlement and License Agreement with Abbott Diabetes Care (ABT). The Settlement Agreement was entered into in full settlement of all pending patent infringement legal proceedings brought by Abbott against the Company. The Settlement Agreement obligates the parties to promptly file a joint stipulation of dismissal of all pending legal proceedings.The Settlement Agreement does not obligate the company to pay any royalties or any other form of financial compensation. The Settlement Agreement provides for a royalty-free, worldwide, non-exclusive, non-sublicensable cross-license of certain patents. The company receives a limited license from Abbott to the patents that Abbott has alleged that the company infringed. The company grants to Abbott a limited license of certain patents with an actual filing date prior to January 1, 2005. In addition, each party agrees not to (1) sue the other party for patent infringement based on certain of their respective continuous glucose monitoring products, and (2) challenge any patent or patent application held by the other party, subject to certain limited exceptions, in each case, until March 31, 2021. The cross-license and mutual covenant not to sue granted to each party do not apply to the type of sensor technology used by the other party. Comments taken from an 8-K filing.
News For DXCM;ABT From The Last 14 Days
Check below for free stories on DXCM;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 14, 2014
16:30 EDTABTOn The Fly: Closing Wrap
Subscribe for More Information
12:21 EDTABTOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTABTAbbott CEO aims to boost medical device line, Reuters says
Subscribe for More Information
09:16 EDTABTOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:55 EDTABTMylan says does not anticipate regulatory hurdles prohibiting close of deal
08:49 EDTABTMylan says Abbott assets unlike other mature generic drug portfolios
Subscribe for More Information
08:36 EDTABTMylan accretive tax inversion deal makes sense, says UBS
Subscribe for More Information
08:27 EDTABTMylan sees Abbott transaction to be 'immediately and significantly accretive'
Subscribe for More Information
08:26 EDTABTMylan sees $10B in pro forma 2014 sales after closing Abbott deal
Subscribe for More Information
08:12 EDTABTMylan says Abbott deal 'first in series' of planned transactions
Subscribe for More Information
07:28 EDTABTMylan to host conference call
Subscribe for More Information
07:20 EDTABTAbbott to host conference call
Conference call to discuss agreement to sell developed markets branded generics pharmaceuticals business to Mylan will be held on July 14 at 9:30 am. Webcast Link
06:33 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:33 EDTABTMylan to acquire Abbott assets in all-stock transaction valued at about $5.3B
Subscribe for More Information
06:31 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
July 13, 2014
20:22 EDTABTMylan near buying Europe-based drug portfolio from Abbott, Reuters says
Subscribe for More Information
July 11, 2014
09:21 EDTDXCMDexCom outlook has improved, says Sterne Agee
Subscribe for More Information
July 10, 2014
15:55 EDTABTJoint venture with Fonterra a 'smart move' for Abbott, says Wells Fargo
Subscribe for More Information
14:01 EDTABTAbbott and Fonterra to form strategic alliance for dairy farming in China
Subscribe for More Information
08:10 EDTABTMorgan Stanley's Vintage Values 2015 list selected
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use